Table 1. Data of phase III clinical trials using the naltrexone/bupropion combination.

Study	Duration	Patients	Treatment groups	Dropout	Weight loss	≥5% weight loss
COR-I[8]	56 weeks	n = 1742	1) 32 mg NAL+360 mg BUP	49%	-6.1%	48%
		Inclusion criteria:	2) 16 mg NAL+360 mg BUP	51%	-5.0%	39%
		• BMI = 30-45 Kg/m^2 or	3) Placebo	50%	-1.3%	16%
		• BMI = 27-45 Kg/m^2, hypertension, dyslipidaemia	Behavioral therapy: ancillary			
COR-II[15]	56 weeks	n = 1496	1) 32 mg NAL+360 mg BUP	46%	-6.4%	51%
		Inclusion criteria:	2) Placebo	46%	-1.2%	17%
		as in COR-I	Behavioral therapy: ancillary			
		Exclusion criteria: DM				
COR-BMOD[14]	56 weeks	n = 793	1) 32 mg NAL+360 mg BUP	42%	-9.3%	66%
		Inclusion criteria:	2) Placebo	42%	-5.1%	43%
		as in COR-I	Behavioral therapy: intensive			
		Exclusion criteria: DM				
COR-Diabetes[16]	56 weeks	n = 505	1) 32 mg NAL+360 mg BUP	48%	-5.0%	45%
		Inclusion criteria:	2) Placebo	41%	-1.8%	19%
		Type 2 DM, BMI = 27-45 Kg/m^2, HbA1c = 7-10%, Glc <270 mg/dL	Behavioral therapy: ancillary			
NB-201[12]	48 weeks	n = 419	1) 16 mg NAL+400 mg BUP	45%	-5.4%	52%
		Inclusion criteria:	2) 32 mg NAL+400 mg BUP	36%	-5.4%	51%
		BMI = 30-40 Kg/m^2,	3) 48 mg NAL+400 mg BUP	63%	-4.3%	39%
		nonsmokers,	4) 400 mg BUP	33%	-2.7%	26%
		normotensive,	5) 48 mg NAL	46%	-1.2%	10%
		LDL-C <190 mg/dL,	6) placebo	32%	-0.8%	15%
		TG <400 mg/dL, Glc <140 mg/dL				
Greenway et al[11]	24 weeks	n = 238	1) 50 mg NAL+300 mg BUP	43%	-3.7%	32%
		Inclusion criteria:	2) 300 mg BUP+placebo	32%	-3.2%	26%
		BMI = 30-40 Kg/m^2	3) 50 mg NAL+placebo	43%	-1.7%	15%
			4) Placebo+placebo	36%	-0.6%	12%

BMI: Body mass index; BUP: Bupropion; DM: Diabetes mellitus; Glc: Fasting blood glucose; HbA1c: Glycated hemoglobin; LDL-C: Low density lipoprotein-cholesterol; NAL: Naltrexone; TG: Serum triglycerides.